COVID-19 Home Test Kits Reimbursable under FSAs, HSAs

Under new guidance issued by the IRS, at-home COVID-19 testing kits will be considered a reimbursable medical expense under the three main health care savings vehicles offered to employees.

This new guidance adds to the list of personal COVID-19-related expenses for which employees can seek reimbursement under:

  • Health savings accounts
  • Health reimbursement arrangements, and
  • Flexible spending accounts.

This is good news as these home tests become more common during this stretch of the pandemic.

The IRS earlier announced that personal protective equipment for use in preventing infection and spread of COVID-19 is also reimbursable by HSAs, FSAs and HRAs. That includes:

  • Masks,
  • Sanitary wipes, and
  • Hand sanitizers.

What to do

If you offer one of the above savings vehicles, you may need to amend your group health plan’s language, unless the plan is drafted to reimburse all IRS-permitted expenses. In that case, you can leave it as is.

If, however, the plan lists all permitted expenses, you’ll need to amend it. If you plan to set the effective date for 2021, say Sept. 15, you should make the amendment no later than Dec. 31, 2021 for it to be effective.

Regardless of whether you have to change the plan or not, you should notify all participating staff of the change so they can take advantage of their plan if they need to.

Recent & Related

HDHP Enrollment Slipping: What It Means for Employers

HDHP Enrollment Slipping: What It Means for Employers

For years, high-deductible health plans have been the most common type of health insurance that employers offer. HDHPs surged in popularity between 2013 and 2021, peaking at 55.7% enrollment. But in a sharp reversal, enrollment in these plans has now fallen for...

read more
What You Need to Know About the EEOC’s New DEI Guidance

What You Need to Know About the EEOC’s New DEI Guidance

New DEI Guidance from the Equal Employment Opportunity Commission (EEOC) and the Department of Justice (DOJ) is reshaping the legal landscape for workplace resource and affinity groups. This comes on the heels of a series of executive orders issued by President Trump...

read more
The GLP-1 Dilemma: How Employers Can Take Control

The GLP-1 Dilemma: How Employers Can Take Control

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity and Wegovy, into their group health plans, as they must balance the cost of the group health plan against the interests of participants...

read more